Literature DB >> 11801464

Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance.

Antonio Cuneo1, Renato Bigoni, Gian Matteo Rigolin, Maria Grazia Roberti, Antonella Bardi, Francesco Cavazzini, Raffaella Milani, Claudia Minotto, Alessia Tieghi, Matteo Della Porta, Paola Agostini, Elisa Tammiso, Massimo Negrini, Gianluigi Castoldi.   

Abstract

BACKGROUND AND OBJECTIVES: Chromosome 11q22.3-23.1 deletions involving the ataxia-teleangiectasia mutated (ATM) locus (11q-/ATM+/-) are detected at diagnosis in 10-20% of cases of B-cell chronic lymphocytic leukemia (CLL) and are associated with a relatively aggressive disease. The aim of this study was to ascertain whether 11q-/ATM+/- may appear late during the course of the disease and to analyze its possible correlation with disease evolution. DESIGN AND METHODS: Eighty-two patients with CLL and related disorders, i.e. CLL/PL and prolymphocytic leukemia (PLL), without 11q- at diagnosis were sequentially ascertained at 1-2 year intervals by conventional cytogenetic analysis (CCA) and fluorescence in situ hybridization (FISH), using an ATM-specific probe.
RESULTS: Eight patients acquired a submicroscopic 11q deletion 13-43 months after diagnosis: the diagnosis at presentation was CLL in 3 cases, CLL/PL in 3 cases and PLL in 2 cases. A 13q14 deletion preceded the development of 11q- in four patients; additional aberrations included +12 (three cases), 17p13 deletion and 6q21 deletion (one case each). The acquisition of the 11q deletion was more frequently found in those patients presenting with CLL/PL and PLL than typical CLL (p=0.0016) and with splenomegaly (p=0.003). Follow-up data showed that karyotype evolution (p=0.009) and cytological transformation (p<0.001) were associated with the acquisition of this cytogenetic lesion. The variables predicting for a shorter survival in this series included the 11q deletion (p=0.03), along with other classical clinicobiological parameters (performance status, advanced stage, splenomegaly, elevated serum beta2 microglobulin and lactate dehydrogenase levels. INTERPRETATION AND
CONCLUSIONS: a) Submicroscopic 11q deletion involving the ATM locus may, in some instances, represent a secondary change in CLL, CLL/P and PLL, suggesting that sequential FISH analyses are necessary to detect this chromosome anomaly in some patients; b) the acquisition of 11q-/ATM deletion may play a role in determining cytological transformation and disease progression of CLL and related disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11801464

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  6 in total

1.  Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma.

Authors:  Nicole Y Fang; Timothy C Greiner; Dennis D Weisenburger; Wing C Chan; Julie M Vose; Lynette M Smith; James O Armitage; R Aeryn Mayer; Brian L Pike; Francis S Collins; Joseph G Hacia
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-15       Impact factor: 11.205

2.  ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele.

Authors:  Anna Skowronska; Belinda Austen; Judith E Powell; Victoria Weston; David G Oscier; Martin J S Dyer; Estella Matutes; Guy Pratt; Christopher Fegan; Paul Moss; Malcolm A Taylor; Tatjana Stankovic
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

3.  Prognostic signature and clonality pattern of recurrently mutated genes in inactive chronic lymphocytic leukemia.

Authors:  A M Hurtado; T-H Chen-Liang; B Przychodzen; C Hamedi; J Muñoz-Ballester; B Dienes; M D García-Malo; A I Antón; F de Arriba; R Teruel-Montoya; F J Ortuño; V Vicente; J P Maciejewski; A Jerez
Journal:  Blood Cancer J       Date:  2015-08-28       Impact factor: 11.037

Review 4.  Small Non-Coding RNAs in Leukemia.

Authors:  Veronica Balatti; Carlo M Croce
Journal:  Cancers (Basel)       Date:  2022-01-20       Impact factor: 6.639

Review 5.  Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go.

Authors:  Anna Puiggros; Gonzalo Blanco; Blanca Espinet
Journal:  Biomed Res Int       Date:  2014-05-22       Impact factor: 3.411

Review 6.  Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review.

Authors:  Francesco Autore; Paolo Strati; Luca Laurenti; Alessandra Ferrajoli
Journal:  Haematologica       Date:  2018-05-10       Impact factor: 9.941

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.